- Home
- MRUS vs FCN Comparison
MRUS vs FCN Comparison
Compare MRUS & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- FCN
- Stock Information
- Founded
- MRUS 2003
- FCN 1982
- Country
- MRUS Netherlands
- FCN United States
- Employees
- MRUS N/A
- FCN N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- FCN Professional Services
- Sector
- MRUS Health Care
- FCN Consumer Discretionary
- Exchange
- MRUS Nasdaq
- FCN Nasdaq
- Market Cap
- MRUS 5.1B
- FCN 5.1B
- IPO Year
- MRUS 2016
- FCN 1996
- Fundamental
- Price
- MRUS $96.19
- FCN $163.55
- Analyst Decision
- MRUS Buy
- FCN Hold
- Analyst Count
- MRUS 17
- FCN 2
- Target Price
- MRUS $94.94
- FCN $169.00
- AVG Volume (30 Days)
- MRUS 1.3M
- FCN 287.0K
- Earning Date
- MRUS 10-31-2025
- FCN 10-23-2025
- Dividend Yield
- MRUS N/A
- FCN N/A
- EPS Growth
- MRUS N/A
- FCN N/A
- EPS
- MRUS N/A
- FCN 7.77
- Revenue
- MRUS $56,606,000.00
- FCN $3,693,035,000.00
- Revenue This Year
- MRUS $52.81
- FCN $1.50
- Revenue Next Year
- MRUS N/A
- FCN $6.66
- P/E Ratio
- MRUS N/A
- FCN $20.98
- Revenue Growth
- MRUS 57.54
- FCN N/A
- 52 Week Low
- MRUS $33.19
- FCN $149.31
- 52 Week High
- MRUS $96.28
- FCN $208.28
- Technical
- Relative Strength Index (RSI)
- MRUS 72.69
- FCN 50.43
- Support Level
- MRUS $95.74
- FCN $161.37
- Resistance Level
- MRUS $96.18
- FCN $166.63
- Average True Range (ATR)
- MRUS 0.36
- FCN 3.20
- MACD
- MRUS -0.39
- FCN -0.13
- Stochastic Oscillator
- MRUS 89.43
- FCN 48.46
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.